Imatinib is the drug of first choice for most patients with chronic phase 
chronic myeloid leukemia (CML). Although it is generally well tolerated, a 
number of hematological and nonhematological side-effects have been described. 
We report here that imatinib induces hypophosphatemia in a high proportion of 
our series of CML patients previously treated with interferon alpha, and that 
this previously unreported side effect is associated with response.